{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-22-000036","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2022-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.812370+00:00","generated_at":"2026-06-23T00:35:10.739441+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vertex Q3 product revenue $2.33B (+18% YoY); raises FY22 guidance to $8.8-8.9B","bullets":["Product revenue $2.334B, up 18% from Q3 2021; TRIKAFTA/KAFTRIO contributed $2.011B.","GAAP diluted EPS $3.59; non-GAAP diluted EPS $4.01, up 14% YoY.","Full-year 2022 product revenue guidance raised to $8.8-8.9B from prior $8.6-8.7B.","Initiating global regulatory submissions for exa-cel (sickle cell/beta thalassemia) in 2022; Phase 3 for VX-548 (acute pain) started.","Cash and marketable securities $11.5B as of Sept 30, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-22-000036","json":"https://secwatch.observer/filing/0000875320-22-000036.json","markdown":"https://secwatch.observer/filing/0000875320-22-000036.md","text":"https://secwatch.observer/filing/0000875320-22-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000036/0000875320-22-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000036/vrtx-20221027.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T00:35:10.739441+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}